239 related articles for article (PubMed ID: 28264884)
1. Functional and structural insight into properdin control of complement alternative pathway amplification.
Pedersen DV; Roumenina L; Jensen RK; Gadeberg TA; Marinozzi C; Picard C; Rybkine T; Thiel S; Sørensen UB; Stover C; Fremeaux-Bacchi V; Andersen GR
EMBO J; 2017 Apr; 36(8):1084-1099. PubMed ID: 28264884
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
3. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
[TBL] [Abstract][Full Text] [Related]
4. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
6. Crystallization and X-ray analysis of monodisperse human properdin.
Pedersen DV; Revel M; Gadeberg TAF; Andersen GR
Acta Crystallogr F Struct Biol Commun; 2019 Feb; 75(Pt 2):0. PubMed ID: 30713161
[TBL] [Abstract][Full Text] [Related]
7. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
8. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
9. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
Vuagnat BB; Mach J; Le Doussal JM
Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
[TBL] [Abstract][Full Text] [Related]
10. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
11. Salivary complement inhibitors from mosquitoes: Structure and mechanism of action.
Strayer EC; Lu S; Ribeiro J; Andersen JF
J Biol Chem; 2021; 296():100083. PubMed ID: 33199367
[TBL] [Abstract][Full Text] [Related]
12. Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond.
Pedersen DV; Lorentzen J; Andersen GR
Immunol Rev; 2023 Jan; 313(1):46-59. PubMed ID: 36097870
[TBL] [Abstract][Full Text] [Related]
13. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
Front Immunol; 2019; 10():2097. PubMed ID: 31552043
[TBL] [Abstract][Full Text] [Related]
14. Expression and characterisation of the thrombospondin type I repeats of human properdin.
Perdikoulis MV; Kishore U; Reid KB
Biochim Biophys Acta; 2001 Aug; 1548(2):265-77. PubMed ID: 11513971
[TBL] [Abstract][Full Text] [Related]
15. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
Harrison RA
Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
17. Structure determination of an unstable macromolecular complex enabled by nanobody-peptide bridging.
Lorentzen J; Pedersen DV; Gadeberg TAF; Andersen GR
Protein Sci; 2022 Oct; 31(10):e4432. PubMed ID: 36173177
[TBL] [Abstract][Full Text] [Related]
18. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
19. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
20. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]